Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04258527 Completed - Solid Tumor Clinical Trials

Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

Start date: March 26, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1 study to investigate the characteristics of PK, PD and safety in subjects with advanced malignancies with FGF/FGFR alterations.

NCT ID: NCT04258462 Recruiting - Renal Cell Cancer Clinical Trials

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

Start date: January 15, 2019
Phase: Phase 2
Study type: Interventional

This feasibility study will evaluate how well hyperpolarized 13C pyruvate magnetic resonance imaging (MRI) scan works in predicting tumor aggressiveness in participants with renal tumors. Hyperpolarized 13C pyruvate is a non-radioactive substance with potential usage in the diagnostic imaging of tumors. Hyperpolarized 13C pyruvate MRI may help doctors determine non-invasively whether a kidney tumor is a benign tumor or cancer, and if cancer, how aggressive it is. This may help doctors and participants with renal tumors in the future to make better treatment decisions.

NCT ID: NCT04257617 Completed - Advanced Cancer Clinical Trials

A Trial of ZL-1201 in Subjects With Advanced Cancer

Start date: May 11, 2020
Phase: Phase 1
Study type: Interventional

First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer

NCT ID: NCT04257240 Completed - Liver Cancer Clinical Trials

Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury

annie-liver
Start date: January 1, 2000
Phase:
Study type: Observational

Severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. Our study aimed at assessing the effect of warm ischemic/reperfusion (I/R) injuries on surgery-to-local recurrence interval and patient overall survival, during major hepatectomies under inflow and outflow vascular control.

NCT ID: NCT04257110 Active, not recruiting - Clinical trials for Locally Advanced/Metastatic HER2 Positive Solid Tumors

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Start date: July 28, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of BB-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, gastric/gastroesophageal junction cancer, bladder cancer and colon cancer, for exploring 1 or more RP2Ds or schedules for expanding/deepening the information/knowledge about clinical safety, clinical pharmacokinetics and anti-tumor activity.

NCT ID: NCT04254926 Completed - Advanced Cancer Clinical Trials

Impact of a Resource-based Life Review Intervention on Advanced Cancer Patients

Revie?
Start date: April 6, 2019
Phase: N/A
Study type: Interventional

The main objective of the present study is to evaluate the effects of the Revie ⊕ intervention on the self-esteem of patients diagnosed with an advanced cancer. A pragmatic, two-arm parallel-group, waitlist randomized controlled trial is conducted. The study takes place in the oncology department of the University Hospitals of Geneva at 3 outpatient units.

NCT ID: NCT04252339 Completed - Clinical trials for Solid Tumor, Unspecified, Adult

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Start date: February 4, 2020
Phase: Phase 1
Study type: Interventional

This study is a multi-center, open-label, dose escalation and expansion study of RLY-1971 in subjects with advanced or metastatic solid tumors.

NCT ID: NCT04250545 Active, not recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Start date: October 26, 2020
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT04250155 Recruiting - Solid Tumors Clinical Trials

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: March 9, 2020
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.

NCT ID: NCT04249947 Active, not recruiting - Prostate Cancer Clinical Trials

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Start date: February 28, 2020
Phase: Phase 1
Study type: Interventional

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.